Gsk (GSK) Change in Receivables (2011 - 2013)
Gsk (GSK) recorded quarterly Change in Receivables of $16.2 million in Q4 2013, down 78.55% quarter-over-quarter from $75.5 million in Q4 2012, and down 78.55% on a YoY basis from $75.5 million in Q4 2012.
Gsk (GSK) Change in Receivables (2011 - 2013) Analysis & Trends
Gsk's Change in Receivables history runs 3 years deep, the most recent figure standing at $16.2 million for Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 595.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -87.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.69 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -504.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 16.19 Mn |
| Dec 31, 2013 | 16.19 Mn |
| Dec 31, 2012 | 75.48 Mn |
| Dec 31, 2012 | 75.48 Mn |
| Dec 31, 2011 | -42.43 Mn |
| Dec 31, 2011 | -42.43 Mn |